How to cite item

Long-term use of sunitinib in metastatic renal cell carcinoma: no unpleasant surprises about tolerability

   
@article{TCR8866,
	author = {Constance Michel and Constance Thibault and Stephane Oudard},
	title = {Long-term use of sunitinib in metastatic renal cell carcinoma: no unpleasant surprises about tolerability},
	journal = {Translational Cancer Research},
	volume = {5},
	number = {Suppl 2},
	year = {2016},
	keywords = {},
	abstract = {Metastatic relapse occurs in approximately 30% of patients who have previously undergone nephrectomy for renal cell carcinoma (1). Anti-angiogenic agents, such as tyrosine kinase inhibitors (TKI), have played a leading role in the treatment of metastatic renal cell carcinoma (mRCC) because it is highly resistant to chemotherapy. Sunitinib is a first-line TKI targeting both the vascular endothelial growth factor receptor (VEGFR) and the platelet-derived growth factor receptor (PDGFR). Treatment of mRCC with sunitinib has been shown to increase progression-free survival (PFS) to 11 months (95% confidence interval 0.32–0.54) versus 5 months with baseline interferon alpha treatment (P24 months’ therapy (2). This chronic use of sunitinib raises the question of long-term safety for patients treated for more than 2 years (3).},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/8866}
}